Study of JP-1366 for maintaining healing in erosive esophagitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new medicine (JP-1366) to see if it can keep the esophagus healed in people who have been treated for erosive esophagitis. You may join if you are an adult with healed erosive esophagitis and have taken standard acid-blocking medication for at least 4 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 to 75 years old
- You have been diagnosed with erosive esophagitis (a type of acid damage to the esophagus) confirmed by an endoscopy within the past 12 weeks
- You have taken a PPI or P-CAB (acid-reducing medication) for at least 4 weeks since that diagnosis
- You have no active stomach or esophageal bleeding, ulcers, or warning signs of cancer (like trouble swallowing, weight loss, or anemia)
- You do not have other serious esophageal conditions such as Barrett's esophagus, narrowing, varices, or infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication to keep erosive esophagitis from coming back after it has healed. If you have healed erosive esophagitis, this treatment may help prevent symptoms and damage from returning.
This trial tests a new medicine, JP-1366, for people with non-erosive GERD (heartburn and acid reflux without visible damage to the esophagus). The goal is to see if it helps control symptoms better than a placebo.
This trial tests a new medication, JP-1366, for people with reflux esophagitis (damage to the esophagus from stomach acid). It aims to see if the drug is safe and effective at healing the esophagus and relieving symptoms like heartburn and regurgitation.
This trial tests a new drug called JP-1366 to see if it can prevent stomach ulcers caused by long-term NSAID use (like ibuprofen or naproxen) for conditions such as arthritis. It may be a good fit if you need to take NSAIDs for at least 24 weeks and have a higher risk of ulcers.
This trial tests vonaprazan (two doses) against esomeprazole to see which better heals moderate-to-severe reflux esophagitis (a damaged esophagus from acid reflux) in 8 weeks. You may qualify if you have had heartburn or regurgitation for at least a month and your doctor found grade B, C, or D damage on an endoscopy.
This trial tests an intervention meant to improve how well adults with eosinophilic esophagitis (EoE) follow their ongoing treatment plan. It may help you stay on your medicine and get better symptom control by making adherence easier.
Hear when a new Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.